1. Michell, RH (2008) Inositol derivatives: evolution and functions. Nature Rev Mol Cell Biol 9, 151–161.
2. Croze, ML & Soulage, CO (2013) Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95, 1811–1827.
3. Hallman, M (2015) Inositol during perinatal transition. NeoReviews 16, e84–e93.
4. Noventa, M, Vitagliano, A, Quaranta, M, et al. (2016) Preventive and therapeutic role of dietary inositol supplementation in periconceptional period and during pregnancy: a summary of evidences and future applications. Reprod Sci 23, 278–288.
5. Greene, NDE, Leung, KY & Copp, AJ (2017) Inositol, neural tube closure and the prevention of neural tube defects. Birth Defects Res 109, 68–80.
6. Monastra, G, Unfer, V, Harrath, AH, et al. (2017) Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecol Endocrinol 33, 1–9.
7. Di Paolo, G & De Camilli, P (2006) Phosphoinositides in cell regulation and membrane dynamics. Nature 443, 651–657.
8. Botelho, RJ (2009) Changing phosphoinositides ‘on the fly’: how trafficking vesicles avoid an identity crisis. Bioessays 31, 1127–1136.
9. Balla, T (2013) Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev 93, 1019–1137.
10. Hammond, GR & Balla, T (2015) Polyphosphoinositide binding domains: key to inositol lipid biology. Biochim Biophys Acta 1851, 746–758.
11. Shears, SB (1998) The versatility of inositol phosphates as cellular signals. Biochim Biophys Acta 1436, 49–67.
12. Shears, SB (2009) Diphosphoinositol polyphosphates: metabolic messengers? Mol Pharmacol 76, 236–252.
13. Monserrate, JP & York, JD (2010) Inositol phosphate synthesis and the nuclear processes they affect. Curr Opin Cell Biol 22, 365–373.
14. Wilson, MS, Livermore, TM & Saiardi, A (2013) Inositol pyrophosphates: between signalling and metabolism. Biochem J 452, 369–379.
15. Low, MG (1987) Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors. Biochem J 244, 1–13.
16. Zurzolo, C & Simons, K (2016) Glycosylphosphatidylinositol-anchored proteins: membrane organization and transport. Biochim Biophys Acta 1858, 632–639.
17. Majumder, AL, Chatterjee, A, Ghosh Dastidar, K, et al. (2003) Diversification and evolution of L-myo-inositol 1-phosphate synthase. FEBS Lett 553, 3–10.
18. Schneider, S (2015) Inositol transport proteins. FEBS Lett 589, 1049–1058.
19. Reynolds, TB (2009) Strategies for acquiring the phospholipid metabolite inositol in pathogenic bacteria, fungi and protozoa: making it and taking it. Microbiology 155, 1386–1396.
20. González-Salgado, A, Steinmann, M, Major, LL, et al. (2015)
Trypanosoma brucei bloodstream forms depend upon uptake of myo-inositol for Golgi complex phosphatidylinositol synthesis and normal cell growth. Eukaryot Cell 14, 616–624.
21. Eagle, H, Oyama, VI, Levy, M, et al. (1957)
Myo-Inositol as an essential growth factor for normal and malignant human cells in tissue culture. J Biol Chem 226, 191–205.
22. Holub, BJ (1986) Metabolism and function of myo-inositol and inositol phospholipids. Annu Rev Nutr 6, 563–597.
23. Henry, SA, Gaspar, ML & Jesch, SA (2014) The response to inositol: regulation of glycerolipid metabolism and stress response signaling in yeast. Chem Phys Lipids 180, 23–43.
24. Ohnishi, T, Murata, T, Watanabe, A, et al. (2014) Defective craniofacial development and brain function in a mouse model for depletion of intracellular inositol synthesis. J Biol Chem 289, 10785–10796.
25. Clements, RS & Darnell, B (1980)
Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr 33, 1954–1967.
26. Wells, WW (1989) Inositol deficiency states as a guide to inositol function. In Inositol Lipids in Cell Signalling, pp. 209–238 [RH Michell, AH Drummond and CP Downes, editors]. London: Academic Press.
27. Schlemmer, U, Frølich, W, Prieto, RM, et al. (2009) Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res 53, Suppl. 2, S330–S375.
28. Dinicola, S, Minini, M, Unfer, V, et al. (2017) Nutritional and acquired deficiencies in inositol bioavailability. Correlations with metabolic disorders. Int J Mol Sci 18, E2187.
29. Wilson, MS, Bulley, SJ, Pisani, F, et al. (2015) A novel method for the purification of inositol phosphates from biological samples reveals that no phytate is present in human plasma or urine. Open Biol 5, 150014.
30. Beemster, P, Groenen, P & Steegers-Theunissen, R (2002) Involvement of inositol in reproduction. Nutr Rev 60, 80–87.
31. Papaleo, E, Unfer, V, Baillargeon, JP, et al. (2009) Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 147, 120–123.
32. Muscogiuri, G, Palomba, S, Laganà, AS, et al. (2016) Inositols in the treatment of insulin-mediated diseases. Int J Endocrinol 2016, 3058393.
33. Chu, SW & Geyer, RP (1982)
Myo -inositol action on gerbil intestine: association of phosphatidylinositol metabolism with lipid clearance. Biochim Biophys Acta 710, 63–70.
34. Chu, SW, Geyer, RP & Walker, WA (1987) Myo-inositol action on gerbil intestine: alterations in alkaline phosphatase activity upon phosphatidylinositol depletion and repletion in vivo
. Biochim Biophys Acta 929, 220–225.
35. Henkel, A & Green, RM (2013) The unfolded protein response in fatty liver disease. Semin Liver Dis 33, 321–329.
36. Lonardo, A, Ballestri, S, Marchesini, G, et al. (2015) Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47, 181–190.
37. Wahlang, B, Beier, JI, Clair, HB, et al. (2013) Toxicant-associated steatohepatitis. Toxicol Pathol 41, 343–360.
38. Bruce, KD & Byrne, CD (2009) The metabolic syndrome: common origins of a multifactorial disorder. Postgrad Med J 85, 614–621.
39. Targher, G, Rossini, M & Lonardo, A (2016) Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine 51, 211–221.
40. Ajmera, VH, Gunderson, EP, Van Wagner, LB, et al. (2016) Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease. Am J Gastroenterol 111, 658–664.
41. Ron, D & Walter, P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nature Rev Mol Cell Biol 8, 519–529.
42. Mori, K (2009) Signalling pathways in the unfolded protein response: development from yeast to mammals. J Biochem 146, 743–750.
43. Lee, AH & Glimcher, LH (2009) Intersection of the unfolded protein response and hepatic lipid metabolism. Cell Mol Life Sci 66, 2835–2850.
44. Walter, P & Ron, D (2011) The unfolded protein response: from stress pathway to homeostatic regulation. Science 334, 1081–1086.
45. Pagliassotti, MJ (2012) Endoplasmic reticulum stress in nonalcoholic fatty liver disease. Annu Rev Nutr 32, 17–33.
46. Malhi, H & Kaufman, RJ (2011) Endoplasmic reticulum stress in liver disease. J Hepatol 54, 795–809.
47. Ariyasu, D, Yoshida, H & Hasegawa, Y (2017) Endoplasmic reticulum (ER) stress and endocrine disorders. Int J Mol Sci 18, pii: E382.
48. Nikawa, J & Yamashita, S (1992) IRE1 encodes a putative protein kinase containing a membrane-spanning domain and is required for inositol phototrophy in Saccharomyces cerevisiae
. Mol Microbiol 6, 1441–1446.
49. Alb, JG Jr, Cortese, JD, Phillips, SE, et al. (2003) Mice lacking phosphatidylinositol transfer protein-alpha exhibit spinocerebellar degeneration, intestinal and hepatic steatosis, and hypoglycemia. J Biol Chem 278, 33501–33518.
50. Alb, JG Jr, Phillips, SE, Wilfley, LR, et al. (2007) The pathologies associated with functional titration of phosphatidylinositol transfer protein alpha activity in mice. J Lipid Res 48, 1857–1872.
51. Nile, AH, Bankaitis, VA & Grabon, A (2010) Mammalian diseases of phosphatidylinositol transfer proteins and their homologs. Clin Lipidol 5, 867–897.
52. Thakur, PC, Stuckenholz, C, Rivera, MR, et al. (2011) Lack of de novo phosphatidylinositol synthesis leads to endoplasmic reticulum stress and hepatic steatosis in cdipt-deficient zebrafish. Hepatology 54, 452–462.
53. Thakur, PC, Davison, JM, Stuckenholz, C, et al. (2014) Dysregulated phosphatidylinositol signaling promotes endoplasmic-reticulum-stress-mediated intestinal mucosal injury and inflammation in zebrafish. Dis Model Mech 7, 93–106.
54. Liu, Y, Wang, W, Shui, G, et al. (2014) CDP-diacylglycerol synthetase coordinates cell growth and fat storage through phosphatidylinositol metabolism and the insulin pathway. PLoS Genet 10, e1004172.
55. Thomas, SE, Dalton, LE, Daly, ML, et al. (2010) Diabetes as a disease of endoplasmic reticulum stress. Diabetes Metab Res Rev 26, 611–621.
56. Cantley, LC (2002) The phosphoinositide 3-kinase pathway. Science 296, 1655–1657.
57. Larner, J, Galasko, G, Cheng, K, et al. (1979) Generation by insulin of a chemical mediator that controls protein phosphorylation and dephosphorylation. Science 206, 1408–1410.
58. Larner, J, Brautigan, DL & Thorner, MO (2010) D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med 16, 543–552.
59. Hecht, ML, Tsai, YH, Liu, X, et al. (2010) Synthetic inositol phosphoglycans related to GPI lack insulin-mimetic activity. ACS Chem Biol 5, 1075–1086.
60. Suzuki, S, Suzuki, C, Hinokio, Y, et al. (2014) Insulin-mimicking bioactivities of acylated inositol glycans in several mouse models of diabetes with or without obesity. PLOS ONE 9, e100466.
61. Hong, JH, Jang, HW, Kang, YE, et al. (2012) Urinary chiro- and myo-inositol levels as a biological marker for type 2 diabetes mellitus. Disease Markers 33, 193–199.
62. Unfer, V, Carlomagno, G, Papaleo, E, et al. (2014) Hyperinsulinemia alters myoinositol to D-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci 21, 854–858.
63. Lin, X, Ma, L, Gopalan, C, et al. (2009) D-chiro-Inositol is absorbed but not synthesised in rodents. Br J Nutr 102, 1426–1434.
64. Galletta, M, Grasso, S, Vaiarelli, A, et al. (2011) Bye-bye chiro-inositol – myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction. Eur Rev Med Pharmacol Sci 15, 1212–1214.
65. Facchinetti, F, Bizzarri, M, Benvenga, S, et al. (2015) Results from the international consensus conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology: the link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol 195, 72–76.
66. Garg, D & Tal, R (2016) Inositol treatment and ART outcomes in women with PCOS. Int J Endocrinol 2016, 1979654.
67. Kim, JI, Kim, JC, Kang, MJ, et al. (2005) Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with Type II diabetes mellitus: a randomized controlled study. Eur J Clin Nutr 59, 456–458.
68. Farias, VX, Macêdo, FH, Oquendo, MB, et al. (2011) Chronic treatment with D-chiro-inositol prevents autonomic and somatic neuropathy in STZ-induced diabetic mice. Diabetes Obes Metab 13, 243–250.
69. Lee, JS, Lee, CM, Jeong, YI, et al. (2007) D-pinitol regulates Th1/Th2 balance via suppressing Th2 immune response in ovalbumin-induced asthma. FEBS Lett 581, 57–64.
70. Hada, B, Yoo, MR, Seong, KM, et al. (2013) D-chiro-inositol and pinitol extend the life span of Drosophila melanogaster
. J Gerontol A Biol Sci Med Sci 68, 226–234.
71. D’Oria, R, Laviola, L, Giorgino, F, et al. (2017) PKB/Akt and MAPK/ERK phosphorylation is highly induced by inositols: novel potential insights into endothelial dysfunction in preeclampsia. Pregnancy Hypertens 10, 107–112.
72. Needham, J (1924) Studies on inositol. II. The synthesis of inositol in the animal body. Biochem J 18, 891–904.
73. Daughaday, WH & Larner, J (1954) The renal excretion of inositol in normal and diabetic human beings. J Clin Invest 33, 326–332.
74. Daughaday, WH, Larner, J & Houghton, E (1954) The renal excretion of inositol by normal and diabetic rats. J Clin Invest 33, 1075–1080.
75. Eriksson, UJ, Borg, LA, Cederberg, J, et al. (2000) Pathogenesis of diabetes-induced congenital malformations. Uppsala J Med Sci 105, 53–84.
76. Chang, HH, Chao, HN, Walker, CS, et al. (2015) Renal depletion of myo-inositol is associated with its increased degradation in animal models of metabolic disease. Am J Physiol Renal Physiol 309, F755–F763.
77. Sun, L, Dutta, RK, Xie, P, et al. (2016)
Myo-inositol oxygenase over-expression accentuates generation of reactive oxygen species and exacerbates cellular injury following high glucose ambience: a new mechanism relevant to the pathogenesis of diabetic nephropathy. J Biol Chem 291, 5688–5707.
78. Tominaga, T, Dutta, RK, Joladarashi, D, et al. (2016) Transcriptional and translational modulation of myo-inositol oxygenase (MIOX) by fatty acids: implications in renal tubular injury induced in obesity and diabetes. J Biol Chem 291, 1348–1367.
79. Liong, S & Lappas, M (2015) Endoplasmic reticulum stress is increased in adipose tissue of women with gestational diabetes. PLOS ONE 10, e0122633.
80. Keane, KN, Cruzat, VF, Carlessi, R, et al. (2015) Molecular events linking oxidative stress and inflammation to insulin resistance and β-cell dysfunction. Oxid Med Cell Longev 2015, 181643.
81. Yung, HW, Alnæs-Katjavivi, P, Jones, CJ, et al. (2016) Placental endoplasmic reticulum stress in gestational diabetes: the potential for therapeutic intervention with chemical chaperones and antioxidants. Diabetologia 59, 2240–2250.
82. Bañuls, C, Rovira-Llopis, S, Martinez de Marañon, A, et al. (2017) Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS. Metabolism 71, 153–162.
83. Zhang, SX, Ma, JH, Bhatta, M, et al. (2015) The unfolded protein response in retinal vascular diseases: implications and therapeutic potential beyond protein folding. Prog Retin Eye Res 45, 111–131.
84. Zhou, L, Ding, S, Li, Y, et al. (2016) Endoplasmic reticulum stress may play a pivotal role in lipid metabolic disorders in a novel mouse model of subclinical hypothyroidism. Sci Rep 6, 31381.
85. Wang, F, Weng, H, Quon, MJ, et al. (2015) Dominant negative FADD dissipates the proapoptotic signalosome of the unfolded protein response in diabetic embryopathy. Am J Physiol Endocrinol Metab 309, E861–E873.
86. Guzel, E, Arlier, S, Guzeloglu-Kayisli, O, et al. (2017) Endoplasmic reticulum stress and homeostasis in reproductive physiology and pathology. Int J Mol Sci 18, pii: E792.
87. Carlomagno, G & Unfer, V (2011) Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci 15, 931–936.
88. Mukai, T, Kishi, T, Matsuda, Y, et al. (2014) A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 29, 55–63.
89. Cockroft, DL, Brook, FA & Copp, AJ (1992) Inositol deficiency increases the susceptibility to neural tube defects of genetically predisposed (curly tail) mouse embryos in vitro
. Teratology 45, 223–232.
90. Greene, ND & Copp, AJ (1997) Inositol prevents folate-resistant neural tube defects in the mouse. Nature Med 3, 60–66.
91. Bizzarri, M, Cucina, A, Dinicola, S, et al. (2016) Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation? Med Hypotheses 91, 1–5.
92. Cogram, P, Hynes, A, Dunlevy, LPE, et al. (2004) Specific isoforms of protein kinase C are essential for prevention of folate-resistant neural tube defects by inositol. Hum Mol Genet 13, 7–14.
93. Artini, PG, Casarosa, E, Carletti, E, et al. (2017)
In vitro effect of myo-inositol on sperm motility in normal and oligoasthenospermia patients undergoing in vitro fertilization. Gynecol Endocrinol 33, 109–112.
94. Michell, RH (2013) Inositol lipids: from an archaeal origin to phosphatidylinositol 3,5-bisphosphate faults in human disease. FEBS J 280, 6281–6294.
95. Morii, H, Kiyonari, S, Ishino, Y, et al. (2009) A novel biosynthetic pathway of archaetidyl-myo-inositol via archaetidyl-myo-inositol phosphate from CDP-archaeol and D-glucose 6-phosphate in methanoarchaeon Methanothermobacter thermautotrophicus cells. J Biol Chem 284, 30766–30774.
96. Vance, JE (2015) Phospholipid synthesis and transport in mammalian cells. Traffic 16, 1–18.
97. Jani, NM & Lopes, JM (2009) Regulated transcription of the Saccharomyces cerevisiae phosphatidylinositol biosynthetic gene, PIS1, yields pleiotropic effects on phospholipid synthesis. FEMS Yeast Res 9, 552–564.
98. Dawson, RM & Eichberg, J (1965) Diphosphoinositide and triphosphoinositide in animal tissues. Extraction, estimation and changes post mortem. Biochem J 96, 634–643.
99. Michell, RH, Hawthorne, JN, Coleman, R, et al. (1970) Extraction of polyphosphoinositides with neutral and acidified solvents. A comparison of guinea-pig brain and liver, and measurements of rat liver inositol compounds which are resistant to extraction. Biochim Biophys Acta 210, 86–91.
100. Anderson, KE, Kielkowska, A, Durrant, TN, et al. (2013) Lysophosphatidylinositol-acyltransferase-1 (LPIAT1) is required to maintain physiological levels of PtdIns and PtdInsP(2) in the mouse. PLOS ONE 8, e58425.
101. Andreyev, AY, Fahy, E, Guan, Z, et al. (2010) Subcellular organelle lipidomics in TLR-4-activated macrophages. J Lipid Res 51, 2785–2797.
102. Shulga, YV, Myers, DS, Ivanova, PT, et al. (2010) Molecular species of phosphatidylinositol-cycle intermediates in the endoplasmic reticulum and plasma membrane. Biochemistry 49, 312–317.
103. Westrate, LM, Lee, JE, Prinz, WA, et al. (2015) Form follows function: the importance of endoplasmic reticulum shape. Annu Rev Biochem 84, 791–811.
104. Nixon-Abell, J, Obara, CJ, Weigel, AV, et al. (2016) Increased spatiotemporal resolution reveals highly dynamic dense tubular matrices in the peripheral ER. Science 354, pii: aaf3928.
105. Waugh, MG, Minogue, S, Clayton, EL, et al. (2011) CDP-diacylglycerol phospholipid synthesis in detergent-soluble, non-raft, membrane microdomains of the endoplasmic reticulum. J Lipid Res 52, 2148–2158.
106. D’Souza, K, Kim, YJ, Balla, T, et al. (2014) Distinct properties of the two isoforms of CDP-diacylglycerol synthase. Biochemistry 53, 7358–7367.
107 Bochud, A & Conzelmann, A (2015) The active site of yeast phosphatidylinositol synthase Pis1 is facing the cytosol. Biochim Biophys Acta 1851, 629–640.
108 Kim, YJ, Guzman-Hernandez, ML & Balla, T (2011) A highly dynamic ER-derived phosphatidylinositol-synthesizing organelle supplies phosphoinositides to cellular membranes. Dev Cell 21, 813-–8824.
109. Kim, YJ, Guzman-Hernandez, ML & Balla, T (2013) Inositol lipid regulation of lipid transfer in specialized membrane domains. Trends Cell Biol 23, 270–278.
110. Nishimura, T, Tamura, N, Kono, N, et al. (2017) Autophagosome formation is initiated at phosphatidylinositol synthase-enriched ER subdomains. EMBO J 36, 1719–1735.
111. English, AR & Voeltz, GK (2013) Rab10 GTPase regulates ER dynamics and morphology. Nat Cell Biol 15, 169–178.
112. Bahmanyar, S (2015) Spatial regulation of phospholipid synthesis within the nuclear envelope domain of the endoplasmic reticulum. Nucleus 6, 102–106.
113. D’Souza, K & Epand, RM (2014) Enrichment of phosphatidylinositols with specific acyl chains. Biochim Biophys Acta 1838, 1501–1508.
114. Lee, HC, Inoue, T, Sasaki, J, et al. (2012) LPIAT1 regulates arachidonic acid content in phosphatidylinositol and is required for cortical lamination in mice. Mol Biol Cell 23, 4689–4700.
115. Johansen, A, Rosti, RO, Musaev, D, et al. (2016) Mutations in MBOAT7, encoding lysophosphatidylinositol acyltransferase I, lead to intellectual disability accompanied by epilepsy and autistic features. Am J Hum Genet 99, 912–916.
116. Mancina, RM, Dongiovanni, P, Petta, S, et al. (2016) The MBOAT7-TMC4 Variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 150, 1219–1230.
117. Luukkonen, PK, Zhou, Y, Hyötyläinen, T, et al. (2016) The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol 65, 1263–1265.
118. Thabet, K, Asimakopoulos, A, Shojaei, M, et al. (2016) MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat Commun 7, 12757.
119. Eslam, M, Valenti, L & Romeo, S (2018) Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 68, 268–279.
120 Kinoshita, T, Maeda, Y & Fujita, M (2013) Transport of glycosylphosphatidylinositol-anchored proteins from the endoplasmic reticulum. Biochim Biophys Acta 1833, 2473–2478.
121. Chedid, A & Nair, V (1972) Diurnal rhythm in endoplasmic reticulum of rat liver: electron microscopic study. Science 175, 176–179.
122 Cretenet, G, Le Clech, M & Gachon, F (2010) Circadian clock-coordinated 12 hr period rhythmic activation of the IRE1alpha pathway controls lipid metabolism in mouse liver. Cell Metab 11, 47–57.
123. Bass, J & Takahashi, JS (2010) Circadian integration of metabolism and energetics. Science 330, 1349–1354.
124. Soeda, J, Cordero, P, Li, J, et al. (2017) Hepatic rhythmicity of endoplasmic reticulum stress is disrupted in perinatal and adult mice models of high-fat diet-induced obesity. Int J Food Sci Nutr 68, 455–466.
125. Fagone, P & Jackowski, S (2009) Membrane phospholipid synthesis and endoplasmic reticulum function. J Lipid Res 50, Suppl., S311–S316.
126. Snapp, EL, Hegde, RS, Francolini, M, et al. (2003) Formation of stacked ER cisternae by low affinity protein interactions. J Cell Biol 163, 257–269.
127. Ferrero, S, Grados-Torrez, RE, Leivar, P, et al. (2015) Proliferation and morphogenesis of the endoplasmic reticulum driven by the membrane domain of 3-hydroxy-3-methylglutaryl Coenzyme A reductase in plant cells. Plant Physiol 168, 899–914.
128. Christodoulou, A, Santarella-Mellwig, R, Santama, N, et al. (2016) Transmembrane protein TMEM170A is a newly discovered regulator of ER and nuclear envelope morphogenesis in human cells. J Cell Sci 129, 1552–1565.
129. Sriburi, R, Bommiasamy, H, Buldak, GL, et al. (2007) Coordinate regulation of phospholipid biosynthesis and secretory pathway gene expression in XBP-1(S)-induced endoplasmic reticulum biogenesis. J Biol Chem 282, 7024–7034.
130. Bommiasamy, H, Back, SH, Fagone, P, et al. (2009) ATF6alpha induces XBP1-independent expansion of the endoplasmic reticulum. J Cell Sci 122, 1626–1636.
131. Lagace, TA & Ridgway, ND (2013) The role of phospholipids in the biological activity and structure of the endoplasmic reticulum. Biochim Biophys Acta 1833, 2499–2510.
132. Covino, R, Ballweg, S, Stordeur, C, et al. (2016) A eukaryotic sensor for membrane lipid saturation. Mol Cell 63, 49–59.
133. Takewaka, T, Zimmer, T, Hirata, A, et al. (1999) Null mutation in IRE1 gene inhibits overproduction of microsomal cytochrome P450Alk1 (CYP 52A3) and proliferation of the endoplasmic reticulum in Saccharomyces cerevisiae
. J Biochem 125, 507–514.
134. Schuck, S, Prinz, WA, Thorn, KS, et al. (2009) Membrane expansion alleviates endoplasmic reticulum stress independently of the unfolded protein response. J Cell Biol 187, 525–536.
135. Maiuolo, J, Bulotta, S, Verderio, C, et al. (2011) Selective activation of the transcription factor ATF6 mediates endoplasmic reticulum proliferation triggered by a membrane protein. Proc Natl Acad Sci USA 108, 7832–7837.
136. Promlek, T, Ishiwata-Kimata, Y, Shido, M, et al. (2011) Membrane aberrancy and unfolded proteins activate the endoplasmic reticulum stress sensor Ire1 in different ways. Mol Biol Cell 22, 3520–3532.
137. Volmer, R, van der Ploeg, K & Ron, D (2013) Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains. Proc Natl Acad Sci U S A 110, 4628–4633.
138. Masuda, M, Miyazaki-Anzai, S, Keenan, AL, et al. (2015) Saturated phosphatidic acids mediate saturated fatty acid-induced vascular calcification and lipotoxicity. J Clin Invest 125, 4544–4558.
139. Halbleib, K, Pesek, K, Covino, R, et al. (2017) Activation of the unfolded protein response by lipid bilayer stress. Mol Cell 67, 673–684.
140. Kono, N, Amin-Wetzel, N & Ron, D (2017) Generic membrane-spanning features endow IRE1α with responsiveness to membrane aberrancy. Mol Biol Cell 28, 2318–2332.
141. Holthuis, JC & Menon, AK (2014) Lipid landscapes and pipelines in membrane homeostasis. Nature 510, 48–57.
142. Birner, R, Bürgermeister, M, Schneiter, R, et al. (2001) Roles of phosphatidylethanolamine and of its several biosynthetic pathways in Saccharomyces cerevisiae
. Mol Biol Cell 12, 997–1007.
143. Van der Veen, JN, Kennelly, JP, Wan, S, et al. (2017) The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim Biophys Acta 1859, 1558–1572.
144. Stefan, CJ, Trimble, WS, Grinstein, S, et al. (2017) Membrane dynamics and organelle biogenesis—lipid pipelines and vesicular carriers. BMC Biology 15, 102.
145. Wong, LH, Čopič, A & Levine, TP (2017) Advances on the transfer of lipids by lipid transfer proteins. Trends Biochem Sci 42, 516–530.
146. French, PJ, Bunce, CM, Stephens, LR, et al. (1991) Changes in the levels of inositol lipids and phosphates during the differentiation of HL60 promyelocytic cells towards neutrophils or monocytes. Proc Roy Soc B 245, 193–201.
147. Fagone, P, Sriburi, R, Ward-Chapman, C, et al. (2007) Phospholipid biosynthesis program underlying membrane expansion during B-lymphocyte differentiation. J Biol Chem 282, 7591–7605.
148. Kirk, SJ, Cliff, JM, Thomas, JA, et al. (2010) Biogenesis of secretory organelles during B cell differentiation. J Leukoc Biol 87, 245–255.
149. Kakazu, E, Mauer, AS, Yin, M, et al. (2016) Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1α-dependent manner. J Lipid Res 57, 233–245.
150. Croze, ML, Géloën, A & Soulage, CO (2015) Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: benefits of a dietary myo-inositol supplementation. Br J Nutr 113, 1862–1875.
151. Davis, KR, Giesy, SL, Long, Q, et al. (2016) XBP1 Regulates the biosynthetic capacity of the mammary gland during lactation by controlling epithelial expansion and endoplasmic reticulum formation. Endocrinology 157, 417–428.
152. Hasegawa, D, Calvo, V, Avivar-Valderas, A, et al. (2015) Epithelial Xbp1 is required for cellular proliferation and differentiation during mammary gland development. Mol Cell Biol 35, 1543–1556.
153. Oza-Frank, R & Gunderson, EP (2017) In-hospital breastfeeding experiences among women with gestational diabetes. Breastfeed Med 12, 261–268.
154. Gunderson, EP, Hurston, SR, Ning, X, et al. (2015) Lactation and progression to Type 2 diabetes mellitus after gestational diabetes mellitus: a prospective cohort study. Ann Intern Med 163, 889–898.
155. Bahmanyar, S, Biggs, R, Schuh, AL, et al. (2014) Spatial control of phospholipid flux restricts endoplasmic reticulum sheet formation to allow nuclear envelope breakdown. Genes Dev 28, 121–126.
156. Paul, C, Laganà, AS, Maniglio, P, et al. (2016) Inositol’s and other nutraceuticals’ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. Gynecol Endocrinol 32, 431–438.
157. Pundir, J, Psaroudakis, D, Savnur, P, et al. (2018) Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG 125, 299–308.
158. Calogero, AE, Gullo, G, La Vignera, S, et al. (2015)
Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study. Andrology 3, 491–495.
159. Gulino, FA, Leonardi, E, Marilli, I, et al. (2016) Effect of treatment with myo-inositol on semen parameters of patients undergoing an IVF cycle: in vivo study. Gynecol Endocrinol 32, 65–68.
160. Capece, M, Romeo, G, Ruffo, A, et al. (2017) A phytotherapic approach to reduce sperm DNA fragmentation in patients with male infertility. Urologia 84, 79–82.
161. Palmieri, M, Papale, P, Della Ragione, A, et al. (2016)
In vitro antioxidant treatment of semen samples in assisted reproductive technology: effects of myo-inositol on nemaspermic parameters. Int J Endocrinol 2016, 2839041.
162. Montanino Oliva, M, Minutolo, E, Lippa, A, et al. (2016) Effect of myoinositol and antioxidants on sperm quality in men with metabolic syndrome. Int J Endocrinol 2016, 1674950.
163. Montanino Oliva, M, Poverini, R, Lisi, R, et al. (2016) Treating woman with myo-inositol vaginal suppositories improves partner’s sperm motility and fertility. Int J Endocrinol 2016, 7621942.
164. Korosi, T, Barta, C, Rokob, K, et al. (2017) Physiological Intra-Cytoplasmic Sperm Injection (PICSI) outcomes after oral pretreatment and semen incubation with myo-inositol in oligoasthenoteratozoospermic men: results from a prospective, randomized controlled trial. Eur Rev Med Pharmacol Sci 21, 2 Suppl., 66–72.
165. Dinkova, A, Martinov, D & Konova, E (2017) Efficacy of myo-inositol in the clinical management of patients with asthenozoospermia. Eur Rev Med Pharmacol Sci 21, 2 Suppl., 62–65.
166. Chiu, TT, Rogers, MS, Law, EL, et al. (2002) Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 17, 1591–1596.
167. Brusco, GF & Mariani, M (2013) Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci 17, 3095–3102.
168. Bevilacqua, A, Carlomagno, G, Gerli, S, et al. (2015) Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology – assisted reproduction technology. Gynecol Endocrinol 31, 441–446.
169. Vitale, SG, Rossetti, P, Corrado, F, et al. (2016) How to achieve high-quality oocytes? The key role of myo-inositol and melatonin. Int J Endocrinol 2016, 4987436.
170. Wdowiak, A (2016) Myoinositol improves embryo development in PCOS patients undergoing ICSI. Int J Endocrinol 2016, 6273298.
171. Simi, G, Genazzani, AR, Obino, ME, et al. (2017) Inositol and in vitro fertilization with embryo transfer. Int J Endocrinol 2017, 5469409.
172. Minozzi, M, Nordio, M & Pajalich, R (2013) The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci 17, 537-–5540.
173. Kamenov, Z, Kolarov, G, Gateva, A, et al. (2015) Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol 31, 131–135.
174. Unfer, V, Nestler, JE, Kamenov, ZA, et al. (2016) Effects of inositol(s) in women with PCOS: a systematic review of randomized controlled trials. Int J Endocrinol 2016, 1849162.
175. Genazzani, AD (2016) Inositol as putative integrative treatment for PCOS. Reprod Biomed Online 33, 770–780.
176. Benelli, E, Del Ghianda, S, Di Cosmo, C, et al. (2016) A combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol 2016, 3204083.
177. Laganà, AS, Rossetti, P, Buscema, M, et al. (2016) Metabolism and ovarian function in PCOS women: a therapeutic approach with inositols. Int J Endocrinol 2016, 6306410.
178. Pkhaladze, L, Barbakadze, L & Kvashilava, N (2016) Myo-inositol in the treatment of teenagers affected by PCOS. Int J Endocrinol 2016, 1473612.
179. Fruzzetti, F, Perini, D, Russo, M, et al. (2017) Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol 33, 39–42.
180. Crawford, TJ, Crowther, CA, Alsweiler, J, et al. (2015) Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes. The Cochrane Database of Systematic Reviews 2015, issue 12, CD011507.
181. Brown, J, Crawford, TJ, Alsweiler, J, et al. (2016) Dietary supplementation with myo-inositol in women during pregnancy for treating gestational diabetes. The Cochrane Database of Systematic Reviews 2016, issue 9, CD012048.
182. Matarrelli, B, Vitacolonna, E, D’Angelo, M, et al. (2013) Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med 26, 967–972.
183. Gugliani, E, Cagnazzo, E, Gugliano, B, et al. (2013) The prevention of gestational diabetes. J Diabetes Metab 4, 7.
184. DʼAnna, R, Di Benedetto, A, Scilipoti, A, et al. (2015) Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: a randomized controlled trial. Obstet Gynecol 126, 310–315.
185. Rogozińska, E, Chamillard, M, Hitman, GA, et al. (2015) Nutritional manipulation for the primary prevention of gestational diabetes mellitus: a meta-analysis of randomised studies. PLOS ONE 10, e0115526.
186. Celentano, C, Matarrelli, B, Mattei, PA, et al. (2016)
Myo-inositol supplementation to prevent gestational diabetes mellitus. Curr Diab Rep 16, 30.
187. Lubin, V, Shojai, R, Darmon, P, et al. (2016) A pilot study of gestational diabetes mellitus not controlled by diet alone: first-line medical treatment with myoinositol may limit the need for insulin. Diabetes Metab 42, 192–195.
188. Farren, M, Daly, N, McKeating, A, et al. (2017) The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care 40, 759–763.
189. Maeba, R, Hara, H, Ishikawa, H, et al. (2008) Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. J Nutr Sci Vitaminol (Tokyo) 54, 196–202.
190. Giordano, D, Corrado, F, Santamaria, A, et al. (2011) Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause 18, 102–104.
191. Santamaria, A, Giordano, D, Corrado, F, et al. (2012) One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric 15, 490–495.
192. Capasso, I, Esposito, E, Maurea, N, et al. (2013) Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials 14, 273.
193. Ferrari, F, Facchinetti, F, Ontiveros, AE, et al. (2016) The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity. Am J Obstet Gynecol 215, e1–e8.
194. Nas, K & Tűű, L (2017) A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women. Eur Rev Med Pharmacol Sci 21, 2 Suppl., 77–82.
195. Pintaudi, B, Di Vieste, G & Bonomo, M (2016) The Effectiveness of myo-inositol and D-chiro inositol treatment in Type 2 diabetes. Int J Endocrinol 2016, 9132052.
196. Greene, NDE, Leung, KY, Gay, V, et al. (2016) Inositol for the prevention of neural tube defects: a pilot randomised controlled trial. Brit J Nutr 115, 974–983.
197. Howlett, A, Ohlsson, A & Plakkal, N (2015) Inositol in preterm infants at risk for or having respiratory distress syndrome. The Cochrane Database of Systematic Reviews 2015, CD000366 (Epublication ahead of print version).
198. Phelps, DL, Ward, RM, Williams, RL, et al. (2016) Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res 80, 209–217.
199. Nordio, M & Basciani, S (2017) Treatment with myo-Inositol and selenium ensures euthyroidism in patients with autoimmune thyroiditis. Int J Endocrinol 2017, 2549491.
200. Ferrari, SM, Fallahi, P, Di Bari, F, et al. (2017) Myo-inositol and selenium reduce the risk of developing overt hypothyroidism in patients with autoimmune thyroiditis. Eur Rev Med Pharmacol Sci 21, 2 Suppl., 36–42.